X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.
Lead Product(s): Lisinopril
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Zestril
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: TWi Pharmaceuticals, Inc.
Deal Size: $38.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 18, 2023
Details:
Zestril (lisinopril) belongs to a class of drugs known as ACE inhibitors. It works by relaxing blood vessels so blood can flow more easily. Zestril is used to treat high blood pressure (hypertension) in adults and children who are at least 6 years old.
Lead Product(s): Lisinopril
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Zestril
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AZTIQ PHARMA
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 30, 2021
Details:
The announcement showed that Lisinopril Tablets are mainly used for the treatment of essential hypertension (EH) and renal vascular hypertension (RVH) and were originally researched and developed by Astrazeneca and approved for launch in the United States in 1988.
Lead Product(s): Lisinopril
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
